The GenusPlus Group Ltd (ASX: GNP) share price is in focus today after the company announced it will begin construction on the first stage of the TasNetworks North West Transmission Developments project, with total works valued at around $750 million.

What did GenusPlus report?

• TasNetworks has issued a Notice to Proceed to GenusPlus for the Construction Phase of NWTD Stage 1
• Construction work is set to commence immediately and is planned for completion in 2029
• Total project value is approximately $750 million, including Early Works and Early Contractor Involvement phases ($122 million)
• The project covers essential power infrastructure in Tasmania

What else do investors need to know?

The announcement follows several earlier updates from GenusPlus about its agreements with TasNetworks, most recently on 8 May 2026. The project is a major contract win for GenusPlus and represents a significant milestone in its growth, given the scale and long-term nature of the work.

GenusPlus is set to play a central role in delivering critical infrastructure for Tasmania, aiming to create local employment and engage Tasmanian suppliers. This contract demonstrates the company’s ongoing strength in the utilities and infrastructure sector across Australia.

What did GenusPlus management say?

GenusPlus Managing Director, David Riches, said:

Genus has worked closely with TasNetworks to reach this important milestone; and with the start of construction imminent we’re proud to move into the next phase of delivering this critical infrastructure for Tasmania and Australia. We’re committed to creating opportunities for Tasmanians throughout the project, from employing local people to engaging Tasmanian business and suppliers. By combining Genus’ capability and experience with local knowledge and expertise, we can deliver lasting value for the community.

What’s next for GenusPlus?

GenusPlus will now shift focus to delivering the construction phase of the TasNetworks NWTD project, with works scheduled until 2029. The company looks set to benefit from its expanded role as an essential service provider in the power and infrastructure sector.

Investors can expect ongoing updates on project milestones and further information about GenusPlus’ strategy to collaborate with local businesses and deliver benefits to both Tasmania and broader Australia.

GenusPlus share price snapshot

Over the past 12 months, GenusPlus shares have risen 66%, outperforming the All Ordinaries Index (ASX: XAO).

View Original Announcement

The post GenusPlus gets green light for $750m TasNetworks build appeared first on The Motley Fool Australia.

More reading

• Three ASX shares set to rise up to 47% – Expert
• GenusPlus Group FY26 earnings: Record results and outlook

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended GenusPlus Group. The Motley Fool Australia has recommended GenusPlus Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

4DMedical Ltd (ASX: 4DX) shares have been among the best performers on the S&P/ASX 200 index (ASX: XJO) over the past 12 months.

During this time, the medical technology company’s shares have risen a staggering 360%.

But if you thought the gains may be over, think again.

That’s because the team at Bell Potter believes there are still more market-beating returns on offer here over the next 12 months.

What is the broker saying?

Bell Potter notes that 4DMedical released its full-year results last week. And while the company only revealed modest revenue from its lung imaging technology, the broker believes the initial traction is highly meaningful. It said:

Product revenues of $6.9m includes $1.6m in fee for service revenues which we understand includes a portion of revenues billed for CT:VQ on a fee per scan basis. While the quantum of revenues is modest, we regard this initial traction in fee for service revenues as highly meaningful and we expect these revenues will grow exponentially in the coming quarters as awareness grows. 

Elsewhere, the company reported a normalised loss of $33.0m (FY25 loss $35.2m) and net operating cash burn of $31.3m. First revenues are yet to be earned at Simonmed, however, the five academic medical centres contracted for CT:VQ are each using the product on a regular basis.

Looking ahead, the broker sees ongoing traction with clinicians in the US as its major catalyst. It explains:

The major catalyst is the ongoing traction with clinicians in the US. There continues to be a ground swell of support for adoption of CT:VQ particularly amongst pulmonary specialists and interventional pulmonologists in academic hospitals. Inevitably this should radiate to other physicians as evidenced by the Simonmed deal and to some extent in Australia.

Big potential returns for 4DMedical shares

According to the note, in response to the company’s results, the broker has retained its speculative buy rating and $6.00 price target on 4DMedical shares.

Based on its current share price of $3.64, this implies potential upside of approximately 65% for investors over the next 12 months.

To put that into context, a $10,000 investment would turn into around $16,500 by this time next year if Bell Potter is on the money with its recommendation.

Commenting on its bullish view of the stock, the broker said:

4DX enters FY27 with good momentum at large hospital groups in the US. We expect on going revenue traction throughout the course of the year. Maintain Buy (Speculative) rating.

All in all, this could make 4DMedical worth considering if you have a high tolerance for risk and want exposure to the medical technology industry.

The post Why 4DMedical shares could still rise 65% appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• 5 things to watch on the ASX 200 on Monday
• 4DMedical share price rises as FY26 revenue climbs, losses moderate
• Here are the top 10 ASX 200 shares today
• These are the 10 most shorted ASX shares

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Antipa Minerals Ltd (ASX: AZY) share price is in focus after fresh drilling results extended gold-copper mineralisation at its Tim’s Dome prospect in Western Australia, including notable intersections such as 10m at 1.5g/t gold and 0.62% copper.

What did Antipa Minerals report?

• Phase 1 CY2026 drilling included 81 holes for 7,819m across Tim’s Dome, AL01, GEO-01 and Yolanda Trend.
• Key Tim’s Dome results: up to 1m at 10.05g/t gold, 0.62% copper, 0.12% lead and 2.55g/t silver.
• Three new gold-copper anomalies defined at AL01, each 500–700m long, suitable for follow-up drilling.
• Assays at GEO-01 returned 10m at 1.1g/t gold, 0.07% copper and 1,328ppm cobalt.
• Drilling at Yolanda Trend identified a 2.1km copper-arsenic-zinc anomaly, adding new discovery targets.
• Three drill rigs remain active at Tim’s Dome, Minyari Dome and Jezabeel.

What else do investors need to know?

Drilling at Tim’s Dome, part of Antipa’s flagship 100%-owned Minyari Gold-Copper Project, has confirmed broad mineralisation above an untested 1.2km-long AEM conductor. Selected RC holes at Tim’s Dome are now being extended with diamond drilling to directly test this highly prospective target.

Beyond Tim’s Dome, Antipa’s regional exploration continues to define new gold and copper anomalies across AL01 and Yolanda Trend, supporting further drilling and resource growth. The ongoing CY2026 programme remains fully funded, with support from WA’s Exploration Incentive Scheme grants.

What did Antipa Minerals management say?

Managing Director and CEO Roger Mason said:

Batch 3 results have further strengthened Tim’s Dome as one of our priority new discovery targets. We’ve now confirmed gold-copper-lead-silver mineralisation in a further five holes spread over more than a kilometre of strike, directly above the large AEM conductor that remains untested. The geological setting, metal association and geometry of the conductor continue to support the Telfer-style reef interpretation we are currently about to test, with diamond tails on several select RC holes now underway. We expect to reach the AEM conductor target in the coming weeks, and will eagerly await results. Elsewhere, the programme continues to generate additional opportunities, with new anomalies defined at AL01 and along the Yolanda Trend, plus further mineralised lodes extended at GEO-01. Now with three rigs active across Tim’s Dome, Minyari Dome and Jezabeel, and a strong pipeline of targets across the broader Minyari Project we’re set for a productive period of new-discovery focused exploration drilling, as we advance our Minyari Dome Pre-feasibility Study toward completion.

What’s next for Antipa Minerals?

Antipa Minerals will continue its major drilling push across Tim’s Dome, AL01, Yolanda Trend and other prospects, with current focus on diamond core tails at Tim’s Dome to directly test the substantial AEM conductor. Ongoing work at GEO-01 South and Jezabeel, plus design of follow-up RC drilling at AL01, are all aimed at growing mineral resources and finding new discoveries.

The Pre-Feasibility Study for Minyari Dome is also progressing, aiming to unlock further value from Antipa’s 100%-owned 2.9Moz gold and 91kt copper resource base in the Paterson Province. Regular updates are expected as new assay results come to hand.

Antipa Minerals share price snapshot

Over the past 12 months, Antipa Minerals shares are flat, slightly trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement

The post Antipa Minerals extends gold-copper mineralisation at Tim’s Dome appeared first on The Motley Fool Australia.

More reading

• Antipa Minerals drilling update: Tim’s Dome and AL01 drive exploration upside

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.